Skip to main content

Advertisement

SpringerLink
Log in

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Kerbel RS (2007) Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 39(4):150–159

    Article  PubMed  Google Scholar 

  2. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436

    Article  CAS  PubMed  Google Scholar 

  3. Mutsaers AJ (2009) Metronomic chemotherapy. Top Companion Anim Med 24(3):137–143

    Article  PubMed  Google Scholar 

  4. Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M (2005) Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 16(8):1243–1252

    Article  CAS  PubMed  Google Scholar 

  5. Nannini M, Nobili E, Di Cicilia R, Brandi G, Maleddu A, Pantaleo MA, Biasco G (2009) To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemother Pharmacol 64(1):189–193

    Article  PubMed  Google Scholar 

  6. Yamashita K, Nabeshima A, Kondo H, Nagao T, Hara Y, Naritomi Y (2009) A case of metronomic chemotherapy as an alternative cancer therapy for palliation. Nippon Ronen Igakkai Zasshi 46(3):264–268

    Article  PubMed  Google Scholar 

  7. Sung CC, Chang PY, Cheng MF, Sheu LF, Yao NS (2009) Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma. Ann Hematol 88(12):1257–1259

    Article  PubMed  Google Scholar 

  8. Fontana A, Bocci G, Galli L, D’Arcangelo M, Derosa L, Fioravanti A, Orlandi P, Landi L, Bursi S, Minuti G, Bona E, Grazzini I, Antonuzzo A, Danesi R, Falcone A (2010) Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. J Am Geriatr Soc 58(5):986–988

    Article  PubMed  Google Scholar 

  9. Borne E, Desmedt E, Duhamel A, Mirabel X, Dziwniel V, Maire C, Florin V, Martinot V, Penel N, Vercambre-Darras S, Mortier L (2010) Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 28(5):684–689

    Article  CAS  PubMed  Google Scholar 

  10. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98(8):1643–1648

    Article  CAS  PubMed  Google Scholar 

  11. Paoloni MC, Khanna C (2007) Comparative oncology today. Vet Clin North Am Small Anim Pract 37(6):1023–1032

    Article  PubMed  Google Scholar 

  12. Gordon I, Paoloni M, Mazcko C, Khanna C (2009) The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med 6(10):e1000161

    Article  PubMed  Google Scholar 

  13. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8(2):147–156

    Article  CAS  PubMed  Google Scholar 

  14. Piantadosi S (2005) Translational clinical trials: an entropy-based approach to sample size. Clin Trials 2(2):182–192

    Article  PubMed  Google Scholar 

  15. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S (2007) Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 21(4):764–769

    Article  PubMed  Google Scholar 

  16. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13(1):73–80

    Article  CAS  PubMed  Google Scholar 

  17. Veterinary Co-operative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0 (2004). Vet Comp Oncol 2(4):195–213

  18. Marconato L, Lorenzo RM, Abramo F, Ratto A, Zini E (2008) Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 6(2):90–101

    Article  CAS  PubMed  Google Scholar 

  19. Multon JE (1978) Tumors in domestic animals. University of California Press

  20. Cruz-Munoz W, Man S, Kerbel RS (2009) Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 15(15):4867–4874

    Article  CAS  PubMed  Google Scholar 

  21. Cruz-Munoz W, Man S, Xu P, Kerbel RS (2008) Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 68(12):4500–4505

    Article  CAS  PubMed  Google Scholar 

  22. Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2(4 Suppl 1):S134–S139

    CAS  PubMed  Google Scholar 

  23. Man S, Munoz R, Kerbel RS (2007) On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 26(3–4):737–747

    Article  PubMed  Google Scholar 

  24. Porrello A, Cardelli P, Spugnini EP (2004) Pet models in cancer research: general principles. J Exp Clin Cancer Res 23(2):181–193

    CAS  PubMed  Google Scholar 

  25. Klopfleisch R, Lenze D, Hummel M, Gruber AD (2010) Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 10:618

    Article  CAS  PubMed  Google Scholar 

  26. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S (2006) A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 28(11):720–728

    Article  CAS  PubMed  Google Scholar 

  27. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M (2006) High-Dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin’s lymphoma. Clin Cancer Res 12(17):5190–5198

    Article  CAS  PubMed  Google Scholar 

  28. Steinbild S, Arends J, Medinger M, Haring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K (2007) Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients—results of a phase II study. Onkologie 30(12):629–635

    Article  CAS  PubMed  Google Scholar 

  29. Andre N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC (2008) Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 30(7):1336–1340

    Article  CAS  PubMed  Google Scholar 

  30. Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D’Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15(15):4954–4962

    Article  CAS  PubMed  Google Scholar 

  31. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15(24):7652–7657

    Article  CAS  PubMed  Google Scholar 

  32. Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G (2010) Metronomic chemotherapy for metastatic prostate cancer: a ‘young’ concept for old patients? Drugs Aging 27(9):689–696

    Article  CAS  PubMed  Google Scholar 

  33. Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N (2006) Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol 29(3):232–239

    Article  CAS  PubMed  Google Scholar 

  34. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40–48

    CAS  PubMed  Google Scholar 

  35. Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, Sellon R, Bryan JN (2011) Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 25(2):278–284

    Article  CAS  PubMed  Google Scholar 

  36. Elmslie RE, Glawe P, Dow SW (2008) Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 22(6):1373–1379

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Prof. Jacopo Vannozzi, Prof. Franco Bocci, Dr. Giacomo Allegrini and Dr. Andrea Fontana for their assistance and precious suggestions.

The study has been funded, in part, by AIRC to G.B.

Author information

Authors and Affiliations

  1. Department of Veterinary Clinics, Veterinary Teaching Hospital, University of Pisa, Pisa, Italy

    Veronica Marchetti, Mario Giorgi, Riccardo Finotello & Simonetta Citi

  2. Division of Pharmacology, Department of Internal Medicine, Faculty of Medicine and Surgery, University of Pisa, Via Roma, 55, I-56126, Pisa, Italy

    Anna Fioravanti, Bastianina Canu, Paola Orlandi, Teresa Di Desidero, Romano Danesi & Guido Bocci

  3. Istituto Toscano Tumori (ITT), Pisa, Italy

    Guido Bocci

Authors
  1. Veronica Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Giorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Fioravanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Finotello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simonetta Citi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bastianina Canu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paola Orlandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Teresa Di Desidero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Romano Danesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guido Bocci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Bocci.

Additional information

Veronica Marchetti and Mario Giorgi have equally contributed to the study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marchetti, V., Giorgi, M., Fioravanti, A. et al. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs 30, 1725–1730 (2012). https://doi.org/10.1007/s10637-011-9672-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9672-y

Keywords

Search

Navigation